Tvardi Therapeutics, Inc. Asset Resilience Ratio
Tvardi Therapeutics, Inc. asset resilience ratio. Tvardi Therapeutics, Inc. (TVRD) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tvardi Therapeutics, Inc. (TVRD) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tvardi Therapeutics, Inc. (2020–2025)
Asset resilience ratio of Tvardi Therapeutics, Inc. from 2020 to 2025. This chart shows how Tvardi Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read Tvardi Therapeutics, Inc. (TVRD) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tvardi Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Tvardi Therapeutics, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Tvardi Therapeutics, Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Tvardi Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Tvardi Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Tvardi Therapeutics, Inc. Asset Resilience Ratio by Year (2020–2025)
Tvardi Therapeutics, Inc. asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Tvardi Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.42% | $10.08 Million | $32.07 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $43.83 Million | -- |
| 2022-12-31 | 49.34% | $22.25 Million | $45.10 Million | -12.83pp |
| 2021-12-31 | 62.16% | $153.58 Million | $247.06 Million | +7.13pp |
| 2020-12-31 | 55.04% | $149.24 Million | $271.16 Million | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more